Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by Johns Hopkins University.
Recruitment status was  Recruiting
University of Nebraska
Information provided by:
Johns Hopkins University
ClinicalTrials.gov Identifier:
First received: January 19, 2010
Last updated: June 22, 2011
Last verified: January 2010
This research is being done to find out whether abacavir (Ziagen®) lowers the levels of ribavirin (Ribapak®) in the body of persons taking these two drugs.

Condition Intervention Phase
Hepatitis C
Other: Ribavrin
Drug: Abacavir plus Ribavirin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Pharmacokinetic Interactions of Ribavirin and Abacavir in Hepatitis-C Mono-infected Male Subjects Who Previously Failed Ribavirin-based Treatment

Resource links provided by NLM:

Further study details as provided by Johns Hopkins University:

Primary Outcome Measures:
  • To evaluate the effect of abacavir (ABC) on Ribavirin Triphosphate (RBV-TP) intracellular concentrations. [ Time Frame: pre-dose, and 6 and 12 hours post-dose ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the effect of ABC on plasma RBV trough concentrations. [ Time Frame: pre-dose, 6 hours, 12 hours post-dose ] [ Designated as safety issue: No ]

Estimated Enrollment: 28
Study Start Date: December 2009
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ribavirin plus Abacavir Administration Drug: Abacavir plus Ribavirin

Daily RBV 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)


Daily RBV 600 mg orally every 12 hours (Body Weight >75 kg)


Daily ABC 300 mg orally every 12 hours

Active Comparator: RBV alone administration Other: Ribavrin

Daily RBV alone 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)


Daily RBV alone 600 mg orally every 12 hours (Body Weight >75 kg)

Detailed Description:
Abacavir is an anti-HIV drug that belongs to the class of nucleosides reverse transcriptase inhibitors. Ribavirin is a drug used to treat hepatitis C infection. Both abacavir and ribavirin are approved by the Food and Drug administration (FDA). The doses of abacavir and ribavirin used in this study are also FDA approved.Some individuals who have HIV infection also have hepatitis C. It is possible that they may need to take both abacavir to treat HIV and ribavirin to treat hepatitis C. Recent studies suggest that abacavir decreases the level of ribavirin in the body (in the blood and in cells named peripheral blood mononuclear cells or PBMCs). Thus, taking ribavirin and abacavir together could lead to treatment failure for hepatitis C. So it is important to understand how levels of ribavirin medication are affected when the two medications are taken together.

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HCV-monoinfected male subjects who previously failed RBV-based therapy for hepatitis C infection, and are currently not receiving therapy for hepatitis C; at least 18-55 years of age.
  • Negative HIV-1 serology documented by any licensed ELISA test kit within 30 days prior to study entry.
  • Positive HCV antibody documented within 30 days prior to study entry.
  • Negative HLA-B*5701 test documented within 30 days prior to study entry.
  • Ability and willingness of subject to provide a signed informed consent and comply with study requirements.
  • All male subjects must not participate in a conception process (e.g., active attempt to impregnate, sperm donation, in vitro fertilization). If participating in sexual activity that could lead to pregnancy, male subjects must take every precaution to avoid risk of pregnancy for their female partners by using reliable contraception (condom) while receiving study therapy and for 6 months following permanent discontinuation of study therapy. Subjects will also be instructed to counsel their female partners regarding fetal risk and need for appropriate contraception (e.g., hormonal, barrier) so as a secondary effort to prevent pregnancy even though the female partners will not be study participants.
  • Estimated creatinine clearance ≥50 mL/minute, within 30 days prior to study entry
  • Laboratory values obtained within 30 days prior to study entry:
  • Hgb within the normal limits as defined by the reporting laboratory
  • AST (SGOT), ALT (SGPT), and alkaline phosphatase >5 x ULN as defined by the reporting laboratory.
  • Direct bilirubin ≤1.5 x UNL as defined by the reporting laboratory.
  • Subject has not consumed alcohol in the 48 hours prior to the administration of study drugs.
  • Framingham cardiovascular disease risk score <10%.

Exclusion Criteria:

  • As determined by the investigator, a significant active or previous history of cardiovascular, renal, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, or immunologic disease (s). This inclusive of chronic illnesses such as hypertension, coronary artery disease, arthritis, diabetes, any chronic gastrointestinal condition that may affect drug absorption. History of chronic or acute medical condition that in the opinion of the investigator would jeopardize safety of subjects participating in this study. Any other medical or psychological condition that might, in the opinion of the site investigator, interfere with participation in the study or put subjects at undue risk.
  • History of anemia, hemoglobinopathy or any other cause of or tendency to hemolysis.
  • History of RBV-induced anemia that required dose reduction or discontinuation of RBV therapy while receiving treatment for hepatitis C infection in the past. Patients who required treatment with erythropoietin or blood transfusion for the management of RBV-associated anemia will be excluded from participating in the study.
  • Use of prescription or over-the-counter medications, including herbal products, within 30 days prior to study entry that in the opinion of the investigator would preclude study participation.
  • Men with a pregnant female partner.
  • Active drug use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements, and/or currently receiving methadone replacement therapy for the treatment of substance abuse.
  • Inability of abstaining from alcohol-containing beverages for the duration of the study.
  • Hospitalization or therapy for serious illness within 30 days prior to study entry as judged by the investigator.
  • Known or suspected HSR to study drugs or their formulations.
  • Participation in any investigational drug study within 30 days prior to study entry.
  • Active or history of gout disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01052701

Contact: Christine Radebaugh, RN cradeba1@jhmi.edu
Contact: Yavette Morton (410) 955-1201 ygoldsb1@jhmi.edu

United States, Maryland
Johns Hopkins Drug Development Unit Recruiting
Baltimore, Maryland, United States, 21287
Principal Investigator: Adriana Andrade, MD         
Sub-Investigator: Mark Sulkowksi, MD         
Sub-Investigator: Craig Hendrix, MD         
Sub-Investigator: Courtney Fletcher, PharmD         
Sponsors and Collaborators
Johns Hopkins University
University of Nebraska
Principal Investigator: Adriana Andrade, MD Johns Hopkins University
  More Information

No publications provided

Responsible Party: Adriana Andrade, MD, MPH, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT01052701     History of Changes
Other Study ID Numbers: NA_00023807 
Study First Received: January 19, 2010
Last Updated: June 22, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on February 11, 2016